Meningococcal vaccine group A conjugate
- PDF / 141,219 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 2 Downloads / 187 Views
1
S
Allergic reaction and other toxicities: 4 case reports A spontaneous surveillance system in Niger identified an 18-year-old boy who developed a severe allergic reaction after receiving meningococcal vaccine group A conjugate [MenAfriVac]. A further three patients developed other toxicities after receiving the vaccine [dosages and outcomes not stated]. The boy developed a rash, intensive pruritus, bronchospasm and fever 30 minutes after injection with meningococcal vaccine group A conjugate. He was hospitalised with a diagnosis of acute urticaria. He was classified as an allergic reaction probably related to vaccination. Three other patients developed symptoms after injection with MenAfriVac. Two men, aged 87 and 30 years, developed GI symptoms and urtciaria, respectively, while a 9-month-old girl developed pain at the injection site [times to reaction onsets not stated]. Author comment: "This case was classified as an allergic reaction probably related to vaccination." Chaibou MS, et al. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. Vaccine 30: 5229-5234, No. 35, 27 Jul 2012. Available from: URL: http:// 803077456 dx.doi.org/10.1016/j.vaccine.2012.06.006 - Niger
0114-9954/10/1420-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 22 Sep 2012 No. 1420
Data Loading...
